Repligen Corporation Stock

Equities

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-05-03 pm EDT 5-day change 1st Jan Change
167 USD +0.44% Intraday chart for Repligen Corporation +0.28% -7.09%
Sales 2024 * 638M Sales 2025 * 740M Capitalization 9.33B
Net income 2024 * 33M Net income 2025 * 89M EV / Sales 2024 * 14.1 x
Net cash position 2024 * 315M Net cash position 2025 * 420M EV / Sales 2025 * 12 x
P/E ratio 2024 *
286 x
P/E ratio 2025 *
107 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.44%
1 week+0.28%
Current month+1.74%
1 month-5.79%
3 months-14.84%
6 months+11.10%
Current year-7.09%
More quotes
1 week
151.82
Extreme 151.82
172.00
1 month
151.82
Extreme 151.82
182.21
Current year
151.82
Extreme 151.82
211.13
1 year
110.45
Extreme 110.45
211.13
3 years
110.45
Extreme 110.45
327.32
5 years
65.20
Extreme 65.2
327.32
10 years
15.92
Extreme 15.915
327.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 14-04-30
President 54 23-10-01
Director of Finance/CFO 50 23-09-24
Members of the board TitleAgeSince
Chairman 72 05-08-31
Director/Board Member 58 14-06-11
Director/Board Member 64 23-02-05
More insiders
Date Price Change Volume
24-05-03 167 +0.44% 454,984
24-05-02 166.3 +5.02% 848,499
24-05-01 158.4 -3.56% 909,297
24-04-30 164.2 -1.17% 756,816
24-04-29 166.1 -0.26% 426,055

Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT

More quotes
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
167 USD
Average target price
204.2 USD
Spread / Average Target
+22.22%
Consensus